Turn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but not quite in the way the 1960s counter-culture figure Dr Timothy Leary intended.
The late Harvard psychologist strongly advocated the use of mind-bending drugs – notably lysergic acid diethylamide (LSD) – to expand creativity and engender a general sense of well-being.
Now, the advocates are all about using psychedelics – notably 3,4-methylene-dioxy-meth-amphetamine (MDMA) and psilocybin to treat difficult conditions such as post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), general anxiety, dementia, anorexia and alcohol and nicotine addiction.
Many readers will be aware – and we’re not passing judgment – that MDMA is the party drug ecstasy, better known as molly. Psilocybin is the active component of magic mushrooms, which have long been known to put the fun into fungi.
Other mind-bending substances of interest are LSD and the horse tranquilliser ketamine (also known as the party drug Special K).
As with cannabis, these drugs have a long history of medical experimentation. LSD was first isolated by Swiss chemist Dr Albert Hofmann in 1943, after which he experienced a vivid trip on his bicycle (in more ways than one) after accidently ingesting the drug.
MDMA was first synthesised by German pharma house Merck in 1912. Meanwhile, psilocybin has long been ingested by central and south American indigenous peoples, who discovered their evening mushroom stew had a bit more zing than usual.
In the 1960s psychedelic drugs became synonymous with swingers’ “key parties” and Vietnam war protests. Serious research came to a halt after US President and moral guardian Richard Milhous Nixon (Tricky Dicky – seeing as how we’re using a lot of colloquial expressions) declared a war on drugs – a battle that has lasted much longer than the Indochina one.
As with medical (and recreational) pot, attitudes are changing – albeit slowly.
According to advocacy group Mind Medicine Australia, more than 120 psychedelic trials have been carried out in the last decade.
Mind-blowing valuations
Overseas, psychedelic drug developers are commanding, er, mind-blowing valuations. Take the $US3.2 billion market worth of the German based, Nasdaq listed Atai Life Sciences which is targeting conditions including traumatic brain injury and schizophrenia.
The private, Oxford-based Beckley Psytech raised $US80 million in August and Chicago-based venture capital group Palo Santo in July gathered $US35 million to invest in a portfolio of psychedelic stocks.
Locally, four ASX cannabis stocks have turned (expanded?) their minds to the sector: Emyria, Creso Pharma, Incannex Healthcare and Little Green Pharma.
Backed by tech entrepreneur Daniel Petrie and venture capital fund Possible Ventures, the private Sydney-based Psylo has raised $1.1 million for early research. Earlier, the Melbourne based Psychae Institute pocketed a handy $40 million from a very mysterious, unnamed American biotechnology company.
Navigating the regulatory maze
For drug development to happen in earnest, the rules need to change.
Last year, the local Therapeutic Goods Administration rejected entreaties to reschedule MDMA and psilocybin from schedule nine to schedule eight (as it did for medicinal cannabis in 2016).
Schedule nine means it’s a prohibited drug which can be used in approved clinical trials; schedule eight means it’s a controlled substance that opens the way to registration and reimbursement.
Mind Medicine Australia argued the decision was based on flawed science, including the contention that these substances were addictive.
In April this year the agency agreed to a re-think and commissioned an independent expert review (as you do).
In late September, the three-person expert committee of academics released the results of its review, which was based on a whittled-down sample of nine clinical studies on the two drugs.
To cut a long story short, the advocates seized on the committee’s headline conclusion that both drugs appeared to have “statistically significant” results, but the evidence was strongest for MDMA.
The well-tolerated substances “showed promise in highly selected populations, but only where these medicines are administered in closely supervised settings and with intensive professional support”.
Of course, the advocates weren’t suggesting otherwise. But they did gloss over the committee’s criticisms of the “variable” quality of many of the trials which, for example, included ‘blinded’ participants who appeared well-aware of what they were taking.
The Advisory Committee of Medicines Scheduling meets on November 3, with the TGA expected to announce its decision in the first week of December.
And elsewhere?
Of course, Australia is – duh – just Australia.
In the US, psychedelics were declared a banned substance in 1970, with “no currently accepted medical use”.
Official attitudes have thawed since then, to put it mildly, with the US Food and Drug Administration awarding “breakthrough” status to MDMA and psilocybin, to treat PTSD and treatment-resistant depression (TDR).
In July, the US Congress passed a law compelling the National Institute of Health to fund research into psychedelic and cannabis therapies, with an emphasis on MDMA for PTSD.
In May this year, the agency granted approval to the Multidisciplinary Association of Psychedelic Studies (MAPS) to study the use of MDMA by healthy volunteer therapists.
MAPS has completed 10 FDA-approved MDMA studies so far and is overseeing another seven.
Health Canada has a similar exemption for therapists, which points to the notion of a “guided experience” rather than users being left to pop the pills at home.
Share price 21 cents, market cap $32 million, 12-month share gain 162 per cent
Emyria’s work initially centred on synthetic cannabis as an alternative to the botanical stuff, which varies in quality.
The company started out its ASX life as Emerald Clinics in early 2020. The company still operates these specialist cannabis clinics, from which it gleans a useful bank of client information for its patient database.
Interestingly Emyria notes a “chronic oversupply” of cannabis, with licensed Canadian growers destroying 279,000 kilograms of the stuff in 2020.
That goes against a narrative about medical cannabis being in short supply.
But we digress and so does Emyria, which is developing a “scalable, evidence-based” clinical model for MDMA, in exclusive partnership with Mind Medicine Australia.
The crux of Emyria’s focus is a proposed phase II trial to treat PTSD with MDMA, but it appears some way from being launched.
Emyria also boasts exclusive access to a file of more than 100 MDMA analogues: a library of compounds developed by the University of Western Australia over the last decade.
Emyria is currently browsing through the library for the most useful ones, with screening to date showing “excellent purity and long-term stability.”
Emyria is executive-chaired by Dr Stewart Washer, who is also on the boards of the listed Orthocell, Cynata and Botanix.
Dr Washer and his family interests account for about 19 per cent of Emerald’s register.
Share price 11 cents, market cap $126 million, 12-month share gain 266 per cent
Pot-stock Creso’s ASX journey since listing in 2016 has been unpredictable, to put it politely, and the wild ride continues into the psychedelic sector.
Creso had planned to merge with the Ontario based Red Light Holland, which is not a knock shop but a purveyor of “magic truffles” (psilocybin) to the legal recreational market in the Netherlands.
The new entity would have listed on the Canadian exchange under the code TRIP – and we rue we’ll never see that apt ticker.
In 2019, Creso was to have been taken over by Canadian pot play Pharma Cielo but that one didn’t get past the altar either. However, the acquisition of the smaller Canadian grower Mernova Medicinal was duly completed in 2018.
In March this year, Creso acquired Canadian outfit Halucenex, a clinical stage company focused on using psilocybin to treat PSTD, TRD and anxiety.
Halucenex is one of only three Canadian companies licensed to handle psilocybin – 10 kilograms of the stuff at any one time.
The psilocybin is synthetic: the company doesn’t forage in the fields for one of the 100-plus varieties of mushies containing the active ingredient.
Creso plans a phase II trial focused on using psilocybin for treatment-resistant PTSD. And in lieu of the Red Light Holland merger, the company is putting on its big boy’s pants for a Nasdaq listing.
Creso co-founder Dr Miri Halperin Wernli is also the president of the $US1.2 billion Mind Medicine Inc, which gives a clue about Creso’s likely hallucinogenic path.
In the meantime, the company almost doubled (cannabis derived) revenue in the first (June) half, to $3.06 million, with just over half derived from Mernova.
Share price 44 cents, market cap $417 million, 12-month share gain 283 per cent
This one was formerly known as Impression Healthcare, which developed sports mouthguards under the Gameday brand.
Despite the advocacy of sports stars, it was never a scalable business and the company executed a graceful double pivot into medical cannabis and then psychedelic therapies.
On the cannabis front, Incannex is tackling conditions including traumatic brain injury, rheumatoid arthritis, irritable bowel syndrome and inflammatory lung conditions. Its most advanced program is a phase II, proof-of-concept trial targeting obstructive sleep apnoea.
On the psychedelic side, Incannex has zeroed in on the use of psilocybin for generalised anxiety disorder. The company notes that seven million Americans and one million Australians suffer moderate to severe anxiety, which makes us more neurotic than them on a per-capita basis.
Pending ethics approval, Incannex expects to launch a phase IIa trial at Monash University’s Brainpark facility.
It’s also yarning with the FDA about an investigational new drug application.
The company cites supportive studies undertaken by New York University, the University of California Los Angeles, Johns Hopkins University and London’s Imperial College.
Overall, these studies enrolled just 85 patients, with early results showing the psychedelics could be two to four times more effective as a front-line treatment relative to cognitive behavioral therapy and antidepressants.
Incannex intends to enlist 72 patients in active and placebo arms, undergoing two doses over 10 weeks. They will also undergo weekly psychotherapy sessions.
Incannex chalked up $1.9 million of revenue from cannabis oil sales in the year to June 2021 and lost $8.1 million.
As with Creso, Incannex proposes a Nasdaq listing. In mid-September its shareholders voted overwhelmingly in favor of issuing 180 million shares to facilitate an initial public offer for the listing.
Management is girded by Nasdaq listees such as Compass Pathways, which is pursuing phase II psilocybin trials for treatment-resistant depression and is valued at $US1.25 billion.
Incannex already commands a circa $400 million valuation.
Share price 68.5 cents, market cap $160 million, 12-month share price gain 108 per cent.
In September, Western Australia’s health mandarins granted the medicinal cannabis supplier a licence to supply psilocybin to other eligible parties to carry out research.
The company, which is backed by iron ore magnate Gina Rinehart, also said it was “well advanced in planning to sponsor a ground-breaking Perth-based clinical trial into psilocybin assisted psychotherapy”.
The research pertains to conditions including depression, post-traumatic stress disorder and anxiety.
The company reminds uninitiated folk that ‘magic mushroom’ derived psilocybin induces a psychedelic state through its action on the brain’s 5-hydroxy-tryptamine-2A serotonin receptors.
The company has also appointed Dr Stephen Bright as an adviser.
A “prominent and highly respected voice in psychedelic medicine”, Dr Bright was a co-founder of psychedelic research house Prism and a lecturer in addiction at Edith Cowan University.
“We have developed so much experience over the years through the cannabis industry and we genuinely believe we can now bring that to bear on the development of the psychedelics,” Little Green boss Fleta Solomon said.
In the meantime, Little Green will remain focused on supplying the European market with cannabis flowers and oils from its newly-acquired Danish facility.
Dr Boreham’s diagnosis:
The simple way of viewing the psychedelic therapies sector is being on the same evolutionary route of medical cannabis, but perhaps a decade behind.
Psylo co-founder Josh Ismin reportedly expects a psychedelic treatment on the market within 10 years, while others expect approval in as little as two years. But the usual experience with the FDA is that things take longer than expected, with only two cannabis-based drugs approved to date.
As with pot therapies – but even more so – the regulators appear to be largely unconvinced at this stage.
The narrative is likely to be muddied by demand from the recreational market for blue meanies, gold tops and amanitas*. And the psychedelic push is likely to confound regulatory authorities as they mull the marijuana approvals.
Still, money talks loudest and there’s no doubting the flood of investment into the sector. If the trend continues, we suspect it will be only a matter of time before the first pure-play ASX psychedelic stock emerges.
Creso cites Credence Research suggesting the market for psilocybin alone could be worth up to $US25 billion by 2025.
If such bullish sentiment endures, investors should have the trip of a lifetime.
Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. *Your columnist had to look up these terms and hopefully so do you.
This column first appeared in Biotech Daily
At Stockhead, we tell it like it is. While Incannex and Creso are Stockhead advertisers, they did not sponsor this article.
The post Dr Boreham’s Crucible: 4 ASX stocks focused on a mind-altering $25 billion psilocybin market appeared first on Stockhead.
